Beyond Air XAIR 深 沪
等待开盘 11-06 09:30:00 美东时间
2.19
-0.140
-6.01%
华盛通- 最 高2.31
- 今 开2.27
- 成交量 1.87万股
- 最 低 2.16
- 昨 收 2.33
- 总市值 364.74万
- 52周最高 53.20
- 市盈率 静 --
- 换手率 1.12%
- 52周最低 2.05
- 委 比 66.67%
- 总股本 166.55万
- 历史最高 6564.00
- 量 比 1.11
- 振 幅 6.44%
- 历史最低 2.05
- 每 手 1
- 风险率 9.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
Beyond Air, Inc. announced it will report its Q3 2026 financial results on November 11, 2026. A conference call and webcast will be held at 4:30 p.m. ET that day. Participants can join via phone or webcast, with replay available later. The company focuses on using nitric oxide to treat respiratory and other conditions, and has FDA approval for its LungFit PH system.
10-29 12:00
Beyond Air Reports Record Preliminary Quarterly Revenue Growth
Beyond Air ( ($XAIR) ) has issued an announcement. Beyond Air reported prelimin...
10-08 20:58
Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M Est
Beyond Air (NASDAQ:XAIR) affirms FY2027 sales outlook from $16.000 million-$18.000 million to $16.000 million-$18.000 million vs $16.715 million estimate.
10-08 20:52
Beyond Air Reports Q2 Preliminary Revenue Of ~$2.3M, Reiterates FY26 Revenue Range $16M - $18M
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced preliminary, unaudited revenue of approximately $2.3 million for the quart...
10-08 20:03
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air reported preliminary revenue of $2.3 million for Q3 2026, marking a 30% sequential and 27% year-over-year increase, driven by adoption of its first-generation LungFit PH system. The second-generation system remains under FDA review. The company reaffirms its 2026 revenue guidance of $8 million and expects $16-$18 million for 2027, contingent on FDA approval of the second-generation system.
10-08 12:00
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
Beyond Air, Inc. announced that its management team will participate in the 2026 Cantor Global Healthcare Conference on September 9-11 in New York. A fireside chat will take place on September 10 at 3:55 PM EDT, with a live webcast available on the company’s website, followed by a 90-day replay. Beyond Air is a medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory illnesses, neurological disorders, and so...
09-02 12:00
Pre-Bell Movers | WHLR Rises by 125.9%; Here Are 20 Stocks Moving Premarket (Aug 28)
US stock futures mixed as markets await Fed Chair Warsh’s Jackson Hole speech, with big moves in premarket trading driven by earnings, guidance, and M&A news.
08-28 16:29
Beyond Air secures financing and expands LungFit PH access
Beyond Air ( ($XAIR) ) has shared an update. Beyond Air reported financial resu...
08-19 04:59
Beyond Air (XAIR) 2027财年第一季度业绩电话会议：FDA催化剂，2026年800万美元展望
Beyond Air 2027财年第一季度营收维持在180万美元，毛利率升至13%，管理层重申了2026日历年800万美元的业绩指引。
08-14 08:45
